Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02107794 · ClinicalTrials.gov registry record · NA

Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

A NA study of Graves Disease and Hyperthyroidism, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
93
Enrollment target
1
Study location

NCT02107794: Completed NA study of Graves Disease and Hyperthyroidism, sponsored by Mayo Clinic.

NCT02107794 is a NA study of Graves Disease and Hyperthyroidism that has completed, run by Mayo Clinic. The registered enrollment target is 93 participants, below the 301-participant average among 11 other Graves Disease trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02107794, a NA study of Graves Disease and Hyperthyroidism, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
93 participants
Enrollment target
1
Study location

Study Summary

The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other stakeholders, iii) direct observation of encounters and iv) extensive field-testing. The goal is to create a decision aid that will be rigorously evidence-based, clear and complete, able to be used by clinicians with minimal training time, while satisfying extant standards for rigorous high-quality shared decision making tools.

Primary Outcome

Outcome measure to be assessed through post-visit surveys.

Interventions

  • OTHER Decision Aid

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2012-12
Est. Completion 2015-04
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT02107794 record still lists

NCT02107794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 301-participant average among 11 other Graves Disease trials with a reported enrollment target (69% lower).

The record links to 3 conditions, with Graves Disease appearing as the primary indexed condition, and to 1 intervention - of which Decision Aid is the first listed.

NCT02107794 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT02107794 about?

NCT02107794 is a clinical study titled "Shared Decision Making in Graves Disease - Graves Disease (GD) Choice". The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other...

What is the current status of trial NCT02107794?

This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2012-12. Estimated completion is 2015-04.

What conditions does trial NCT02107794 study?

This clinical trial studies the following conditions: Graves Disease, Hyperthyroidism, Thyroid Disease.

What interventions are being tested in trial NCT02107794?

The interventions under investigation include: Decision Aid (OTHER).

Who is sponsoring clinical trial NCT02107794?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02107794 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graves Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02107794's enrollment target sits among peer trials

93 6th of 11 higher than 6 of 11 other Graves Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02107794, the US trial registry maintained by the National Library of Medicine. NCT02107794 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.